A 17-hydroxyprogesterone test measures a steroid made mainly in the adrenal glands as the body produces cortisol. In women, the test is most often used to screen for nonclassic congenital adrenal hyperplasia, especially when acne, excess facial or body hair, irregular periods, infertility, or unexpectedly high androgen levels could otherwise be attributed to polycystic ovary syndrome. The result cannot diagnose PCOS, and a mildly high value does not automatically mean congenital adrenal hyperplasia. Timing, menstrual-cycle phase, pregnancy, stress, illness, medications, and the laboratory method can all affect the number. For the clearest screening result, clinicians usually prefer an early-morning blood sample during the follicular phase, often within the first several days of a menstrual cycle. Borderline or elevated results may lead to an ACTH stimulation test, repeat measurement by a more specific method, and review of other hormones before a diagnosis is made.
- The 17-OHP test mainly screens for 21-hydroxylase-deficient congenital adrenal hyperplasia, not PCOS itself.
- An early-morning, early-follicular sample is usually the most useful screening specimen in menstruating women.
- A basal value around 200 ng/dL, or 6 nmol/L, often triggers further evaluation, but laboratory cutoffs differ.
- A stimulated value around 1,000 ng/dL, or 30 nmol/L, can support nonclassic congenital adrenal hyperplasia when the clinical picture fits.
- Rapid virilization, very high androgens, severe weakness, vomiting, or low blood pressure needs prompt medical assessment rather than routine follow-up.
Table of Contents
- What the 17-OHP Test Measures
- Why Women Are Tested
- Preparation and Timing
- Understanding 17-OHP Results
- PCOS Versus Nonclassic Congenital Adrenal Hyperplasia
- Follow-Up Testing and Next Steps
- Pregnancy, Medications, and Other Special Situations
What the 17-OHP Test Measures
17-hydroxyprogesterone, usually shortened to 17-OHP, is an intermediate steroid in the pathway the adrenal glands use to make cortisol. It is not the same as progesterone, even though the names are similar. Progesterone is a major reproductive hormone involved in ovulation, the luteal phase, and pregnancy. The 17-OHP measurement is used mainly to investigate adrenal steroid production.
In the most common form of congenital adrenal hyperplasia, an enzyme called 21-hydroxylase does not work normally. This slows the conversion of 17-OHP toward cortisol. The pituitary gland responds to reduced cortisol production by releasing more adrenocorticotropic hormone, or ACTH. ACTH stimulates the adrenal glands, causing 17-OHP and androgen precursors to accumulate. Some of those precursors are diverted into androgen production, which can raise androstenedione and testosterone.
Classic congenital adrenal hyperplasia is usually recognized in infancy or childhood and can include serious cortisol or aldosterone deficiency. Nonclassic congenital adrenal hyperplasia, often called NCCAH, involves partial enzyme activity. It may not become obvious until adolescence or adulthood. A woman with NCCAH may have irregular cycles, hirsutism, acne, scalp hair thinning, difficulty ovulating, or infertility. Those features overlap with PCOS, which is why 17-OHP is often included in a hyperandrogenism evaluation.
The test may be performed by an immunoassay or by liquid chromatography–tandem mass spectrometry, commonly written as LC-MS/MS. LC-MS/MS is generally more specific because it separates similar steroid molecules before measurement. Immunoassays can sometimes overestimate low concentrations through cross-reaction with other steroids. This matters most when the result sits near a diagnostic cutoff.
A single 17-OHP value is a screening clue, not a diagnosis. Interpretation depends on the time of day, cycle phase, symptoms, androgen results, medication use, and assay. The result is often reviewed alongside a testosterone test in women, DHEA-S, androstenedione, and sometimes cortisol.
Why Women Are Tested
Clinicians usually order 17-OHP when they need to distinguish common PCOS-related androgen excess from an inherited adrenal enzyme disorder. Testing is most useful when symptoms or blood tests suggest androgen excess and the diagnosis is not already clear.
Common reasons include:
- New or persistent facial, chest, abdominal, or back hair growth
- Moderate to severe acne that persists beyond adolescence
- Irregular periods, long cycles, or absent periods
- Difficulty ovulating or unexplained infertility
- High testosterone or androstenedione
- Early pubic hair development or rapid growth in adolescence
- A known family history of congenital adrenal hyperplasia
- An ethnic background in which NCCAH is more common
- A partner known to carry a clinically important CYP21A2 gene variant
The test can also be useful when a woman appears to have PCOS but has unusual features. PCOS usually develops gradually. Rapid progression over months, deepening of the voice, increased muscle mass, clitoral enlargement, or marked recession of the frontal hairline is not typical and requires a broader evaluation for severe androgen excess. That evaluation may include ovarian and adrenal imaging as well as several blood tests.
A 17-OHP test is not a general wellness test. It does not measure overall “hormone balance,” predict menopause, assess egg quality, or determine whether a woman can become pregnant naturally. It also does not replace a full PCOS blood test panel when PCOS is suspected. PCOS is diagnosed from a combination of ovulatory dysfunction, clinical or biochemical androgen excess, and ovarian morphology or an accepted alternative criterion, after other causes have been considered.
Women with absent periods often need pregnancy testing first, followed by targeted evaluation of FSH, estradiol, prolactin, TSH, and androgens. In that setting, 17-OHP is most relevant when hirsutism, acne, or high androgen results accompany amenorrhea.
Preparation and Timing
The most informative screening sample is usually drawn early in the morning, often between 7 and 9 a.m. ACTH secretion follows a daily rhythm, and 17-OHP can be higher in the morning than later in the day. A late-afternoon result may therefore be harder to compare with standard screening thresholds.
For menstruating women, clinicians generally prefer the early follicular phase, commonly cycle days 3 through 5 or within the first week after bleeding begins. After ovulation, the corpus luteum produces progesterone and related steroids, and 17-OHP may rise. A luteal-phase sample can look falsely concerning. If a woman has very irregular cycles or no periods, the clinician may draw the sample on any day and interpret it with the menstrual history, estradiol, progesterone, or ultrasound findings.
Fasting is usually not required unless other ordered tests need it. A morning androgen panel may include glucose or insulin tests that do require fasting, so the laboratory instructions should take priority.
Before testing, provide a complete list of medications and supplements. Important examples include:
- Glucocorticoids such as prednisone, hydrocortisone, or dexamethasone
- Combined birth-control pills, progestins, or estrogen therapy
- Fertility medications and recent ovarian stimulation
- Testosterone, DHEA, “adrenal support,” or bodybuilding supplements
- Antiseizure medicines and other drugs that alter steroid metabolism
Do not stop a prescribed medicine without the prescriber’s advice. Glucocorticoids can suppress ACTH and lower 17-OHP. Hormonal contraception can change ovarian and adrenal hormone patterns and may make an androgen workup less representative of the untreated state. A clinician may recommend testing after a medication-free interval when it is safe, but the interval depends on the drug and the reason for treatment.
Acute illness, major physical stress, sleep disruption, and pregnancy can alter steroid concentrations. If the result is unexpected and the woman was ill or the sample was drawn at a suboptimal time, repeating the test under standardized conditions may be more useful than immediately assuming disease.
Understanding 17-OHP Results
Laboratories report 17-OHP in ng/dL, ng/mL, or nmol/L. Unit conversion is essential: 1 ng/mL equals 100 ng/dL, and 1 ng/mL is approximately 3.03 nmol/L. A number that appears dramatically different may simply use a different unit.
There is no universal reference range. Age, menstrual phase, pregnancy, time of collection, and assay method all influence the interval. The laboratory’s own range and comments should be used first.
| Basal result | Approximate meaning | Typical next step |
|---|---|---|
| Below about 200 ng/dL (below about 6 nmol/L) | NCCAH is less likely when the sample was drawn correctly | Review symptoms and other androgen tests |
| About 200–1,000 ng/dL (about 6–30 nmol/L) | Borderline or elevated screening range | Repeat a properly timed sample or perform ACTH stimulation |
| Above about 1,000 ng/dL (above about 30 nmol/L) | Strongly raises suspicion for 21-hydroxylase deficiency | Endocrine evaluation, confirmatory testing, and possible genetics |
These thresholds are practical examples, not self-diagnosis rules. Some laboratories and guidelines use lower or higher screening cutoffs, particularly with LC-MS/MS. A basal value below 200 ng/dL does not absolutely exclude NCCAH when clinical suspicion is high. Conversely, a mild elevation is common in the luteal phase and can occur with PCOS, stress, assay interference, or other adrenal conditions.
Several details can explain an unexpected borderline value. A sample drawn a week before a period may reflect normal luteal steroid production. An immunoassay may detect structurally similar molecules and report a higher concentration than LC-MS/MS. A recent fertility cycle can leave progesterone and related steroids elevated. Pregnancy changes the expected range, and acute illness can increase ACTH-driven adrenal activity. For these reasons, repeating a borderline result under standardized conditions often prevents unnecessary imaging or genetic testing.
A result should also be judged against the severity of symptoms. Consider two women with the same basal value of 240 ng/dL. One has a sample drawn at 4 p.m. in the luteal phase and no androgen symptoms; a properly timed repeat may be all that is needed. The other has lifelong irregular cycles, progressive hirsutism, elevated androstenedione, and a sibling with NCCAH; an ACTH stimulation test would carry greater value. The number is identical, but the pretest probability is not.
What an ACTH stimulation result means
During an ACTH stimulation test, a baseline sample is collected, synthetic ACTH is administered, and 17-OHP is measured again, often at 30 or 60 minutes. A stimulated level around or above 1,000 ng/dL, approximately 30 nmol/L, has traditionally supported NCCAH due to 21-hydroxylase deficiency. The exact cutoff should match the assay and specialist protocol.
A clearly normal response makes NCCAH less likely. A borderline response may lead to repeat testing by LC-MS/MS or CYP21A2 genetic testing. Genetic results can be complex because the gene has many variants, gene conversions, and copy-number changes. A specialist or genetic counselor can explain whether a variant is disease-causing, carrier-only, or uncertain.
Low 17-OHP
A low value is usually not a problem by itself. It may reflect normal physiology, later-day sampling, hormonal suppression, or glucocorticoid use. Low 17-OHP is not used alone to diagnose adrenal insufficiency. Suspected adrenal insufficiency is assessed primarily with cortisol, ACTH, electrolytes, and a cortisol stimulation test.
PCOS Versus Nonclassic Congenital Adrenal Hyperplasia
PCOS and NCCAH can look remarkably similar. Both may cause irregular ovulation, acne, hirsutism, high androgens, and reduced fertility. Some women with either condition have polycystic-appearing ovaries on ultrasound. The distinction matters because the inherited cause, counseling, medication choices, and pregnancy planning differ.
| Feature | PCOS | NCCAH |
|---|---|---|
| Primary mechanism | Multifactorial ovarian, metabolic, and neuroendocrine disorder | Inherited partial deficiency of an adrenal steroid enzyme, usually 21-hydroxylase |
| 17-OHP | Usually normal; mild elevation can occur | Often elevated, especially after ACTH stimulation |
| Insulin resistance | Common but not required | May occur but is not the defining defect |
| Family implications | Familial tendency without a single routine carrier test | Autosomal recessive condition with reproductive genetic implications |
| Treatment focus | Cycles, metabolic risk, androgen symptoms, and fertility goals | Symptoms and fertility; glucocorticoids only in selected situations |
NCCAH is not simply “adrenal PCOS.” It is a specific genetic condition. PCOS is much more common, so most women with gradual hirsutism and irregular cycles will not have NCCAH. Still, checking 17-OHP prevents a treatable inherited disorder from being missed.
The LH-to-FSH ratio does not reliably distinguish the two. DHEA-S can be normal in NCCAH and high in PCOS, so it is not a definitive separator either. The strongest laboratory distinction is a properly timed 17-OHP result followed, when needed, by ACTH stimulation.
Treatment depends on the person’s priorities. Many women with NCCAH who have no troubling symptoms need no daily glucocorticoid. Hirsutism and acne may be managed similarly to PCOS with contraception and antiandrogen treatment when pregnancy is not desired. Women trying to conceive may benefit from specialist care, ovulation assessment, and selective glucocorticoid therapy. The dose should be the lowest that meets the clinical purpose because excess glucocorticoid can cause weight gain, bone loss, high blood pressure, glucose problems, and adrenal suppression.
Follow-Up Testing and Next Steps
An abnormal result should be interpreted as part of a sequence rather than in isolation.
- Confirm collection conditions. Check the time of day, cycle phase, pregnancy status, illness, and medications.
- Verify the units and assay. A result in ng/mL cannot be compared directly with a cutoff written in ng/dL. Ask whether the laboratory used immunoassay or LC-MS/MS.
- Review accompanying hormones. Total testosterone, free testosterone or calculated free testosterone, SHBG, DHEA-S, and androstenedione help describe the androgen pattern.
- Repeat or stimulate when appropriate. A borderline basal value commonly leads to a repeat early-morning follicular sample or an ACTH stimulation test.
- Consider genetics after biochemical evidence. CYP21A2 testing is most informative when hormone results support NCCAH or when reproductive counseling is needed.
The broader evaluation may also include pregnancy testing, TSH, prolactin, FSH, LH, estradiol, glucose or A1C, lipids, and pelvic ultrasound. A hirsutism hormone test panel is tailored to symptoms rather than ordered as the same fixed package for every patient.
Imaging is not triggered by a modestly high 17-OHP alone. Pelvic ultrasound or adrenal imaging becomes more important when testosterone or DHEA-S is markedly elevated, virilization is present, or symptoms progress rapidly. Specialists may also test cortisol pathways when Cushing syndrome or a broader adrenal disorder is suspected.
The following questions can make a follow-up visit more productive:
- Was the sample collected in the morning and, if relevant, during the follicular phase?
- Which assay method was used, and is the cutoff specific to that method?
- Should the result be repeated before an ACTH stimulation test?
- Do the testosterone, SHBG, DHEA-S, and androstenedione results point toward an ovarian or adrenal pattern?
- Would a diagnosis change treatment now, or is testing mainly important for pregnancy planning?
- Is genetic counseling appropriate for the woman, her partner, or other relatives?
Long-term management should follow symptoms and health goals, not repeated 17-OHP measurements alone. A woman treated for fertility may need a different plan from someone seeking acne control, and a woman without symptoms may need counseling rather than medication. When glucocorticoids are prescribed, clinicians usually avoid fully suppressing every adrenal androgen because doing so can expose the patient to more steroid than she needs.
Seek prompt care for rapidly deepening voice, sudden severe hirsutism, clitoral enlargement, major muscle changes, severe abdominal or flank pain, or symptoms of adrenal crisis such as repeated vomiting, profound weakness, fainting, confusion, or very low blood pressure. Those findings require a faster evaluation than routine outpatient retesting.
Pregnancy, Medications, and Other Special Situations
Pregnancy increases several steroid hormones and changes binding proteins. Maternal 17-OHP values also vary by trimester and cannot be interpreted using a nonpregnant follicular-phase range. A high result during pregnancy does not diagnose fetal congenital adrenal hyperplasia. Prenatal genetic counseling and fetal testing, when indicated, follow a separate pathway based on parental variants and specialist assessment.
For a woman with confirmed NCCAH who is planning pregnancy, partner testing may be discussed. Because the condition is autosomal recessive, the risk to a child depends on the specific variants carried by both biological parents. A woman with two disease-associated variants and a partner who carries a severe CYP21A2 variant may have a meaningful chance of a child with classic CAH. Genetic counseling provides a clearer risk estimate than hormone levels alone.
Hormonal contraceptives often reduce ovarian androgen production and increase SHBG. They may improve acne and hirsutism while changing the laboratory picture. DHEA supplements can raise adrenal androgen markers and make the workup misleading. “Natural” adrenal products may contain undeclared steroid-like ingredients, so the exact product name matters.
Women receiving glucocorticoid treatment for NCCAH need periodic clinical review rather than treatment to normalize every androgen number. The aim is symptom control, ovulation support when needed, and avoidance of overtreatment. Bone health, blood pressure, weight, and glucose may require monitoring during long-term therapy.
A normal 17-OHP does not end the evaluation when symptoms are significant. PCOS, thyroid disease, elevated prolactin, medication effects, severe insulin resistance, and rare ovarian or adrenal tumors remain possible. A clearly abnormal result likewise needs confirmation before a lifelong label is applied. Correct timing and confirmatory testing turn an isolated number into a clinically useful answer.
NCCAH can affect people differently even within the same family. One woman may have only mild acne, another may have irregular ovulation, and another may be identified only during fertility testing. Symptoms can change with age, weight, hormonal contraception, pregnancy, and menopause. A biochemical diagnosis therefore does not predict a fixed course, and treatment is not automatically lifelong. Periodic reassessment helps ensure that medication still matches the reason it was started.
It is also important to separate carrier status from disease. A person with one CYP21A2 disease-associated variant is usually a carrier and generally does not have the classic biochemical pattern of NCCAH. Hormone testing and genetic testing answer related but different questions: hormone testing shows how the steroid pathway is functioning, while genetics identifies variants that may explain that function and clarify reproductive risk.
When a borderline result needs a planned repeat
A borderline 17-OHP result is most useful when the repeat is designed to remove avoidable sources of variation. The clinician may ask for an early-morning sample during the follicular phase, before 8 a.m. when practical, and after confirming that hormonal medicines or glucocorticoids have been handled safely. The same laboratory and method can make comparison easier. A repeat that falls clearly below the laboratory’s screening threshold may end the NCCAH workup when symptoms are mild and no other evidence points to the disorder.
When the repeat remains elevated, an ACTH stimulation test may be the next step. Baseline and stimulated values should be interpreted with the assay method and the laboratory’s validated criteria, not with a cutoff copied from a different platform. A stimulated pattern consistent with 21-hydroxylase deficiency can then guide genetic counseling, fertility planning, and treatment decisions. This staged approach reduces both missed diagnoses and unnecessary lifelong labeling.
References
- Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women 2025 (Guideline)
- Evaluating the diagnostic accuracy of androgen measurement in polycystic ovary syndrome: a systematic review and diagnostic meta-analysis to inform evidence-based guidelines 2025 (Systematic Review)
- Approach to androgen excess in women: Clinical and biochemical insights 2022 (Review)
- Nonclassic Congenital Adrenal Hyperplasia: What Do Endocrinologists Need to Know? 2021 (Review)
- Current evaluation of amenorrhea: a committee opinion (2024) 2024 (Committee Opinion)
Disclaimer
This information explains common uses and interpretation of 17-OHP testing but cannot diagnose PCOS, congenital adrenal hyperplasia, or another endocrine condition. Reference ranges and stimulation cutoffs vary by assay, age, menstrual phase, and clinical setting. Discuss an abnormal result with a clinician or endocrinologist, and seek urgent care for severe weakness, fainting, persistent vomiting, or rapidly developing virilization.
